196 related articles for article (PubMed ID: 35846573)
1. Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2.
Prabhakar S; Beauchamp RL; Cheah PS; Yoshinaga A; Haidar EA; Lule S; Mani G; Maalouf K; Stemmer-Rachamimov A; Jung DH; Welling DB; Giovannini M; Plotkin SR; Maguire CA; Ramesh V; Breakefield XO
Mol Ther Methods Clin Dev; 2022 Sep; 26():169-180. PubMed ID: 35846573
[TBL] [Abstract][Full Text] [Related]
2. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
James MF; Han S; Polizzano C; Plotkin SR; Manning BD; Stemmer-Rachamimov AO; Gusella JF; Ramesh V
Mol Cell Biol; 2009 Aug; 29(15):4250-61. PubMed ID: 19451225
[TBL] [Abstract][Full Text] [Related]
3. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.
Giovannini M; Bonne NX; Vitte J; Chareyre F; Tanaka K; Adams R; Fisher LM; Valeyrie-Allanore L; Wolkenstein P; Goutagny S; Kalamarides M
Neuro Oncol; 2014 Apr; 16(4):493-504. PubMed ID: 24414536
[TBL] [Abstract][Full Text] [Related]
4. Loss of the NF2 gene and merlin occur by the tumorlet stage of schwannoma development in neurofibromatosis 2.
Stemmer-Rachamimov AO; Ino Y; Lim ZY; Jacoby LB; MacCollin M; Gusella JF; Ramesh V; Louis DN
J Neuropathol Exp Neurol; 1998 Dec; 57(12):1164-7. PubMed ID: 9862639
[TBL] [Abstract][Full Text] [Related]
5. Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism.
Wong HK; Shimizu A; Kirkpatrick ND; Garkavtsev I; Chan AW; di Tomaso E; Klagsbrun M; Jain RK
Neoplasia; 2012 Feb; 14(2):84-94. PubMed ID: 22431917
[TBL] [Abstract][Full Text] [Related]
6. Generation and Use of Merlin-Deficient Human Schwann Cells for a High-Throughput Chemical Genomics Screening Assay.
Petrilli AM; Fernández-Valle C
Methods Mol Biol; 2018; 1739():161-173. PubMed ID: 29546707
[TBL] [Abstract][Full Text] [Related]
7. The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells.
Bashour AM; Meng JJ; Ip W; MacCollin M; Ratner N
Mol Cell Biol; 2002 Feb; 22(4):1150-7. PubMed ID: 11809806
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of SIRT2 in merlin/NF2-mutant Schwann cells triggers necrosis.
Petrilli A; Bott M; Fernández-Valle C
Oncotarget; 2013 Dec; 4(12):2354-65. PubMed ID: 24259290
[TBL] [Abstract][Full Text] [Related]
9. Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function.
Yang C; Asthagiri AR; Iyer RR; Lu J; Xu DS; Ksendzovsky A; Brady RO; Zhuang Z; Lonser RR
Proc Natl Acad Sci U S A; 2011 Mar; 108(12):4980-5. PubMed ID: 21383154
[TBL] [Abstract][Full Text] [Related]
10. Peroxynitrite supports a metabolic reprogramming in merlin-deficient Schwann cells and promotes cell survival.
Pestoni JC; Klingeman Plati S; Valdivia Camacho OD; Fuse MA; Onatunde M; Sparrow NA; Karajannis MA; Fernández-Valle C; Franco MC
J Biol Chem; 2019 Jul; 294(30):11354-11368. PubMed ID: 31171721
[TBL] [Abstract][Full Text] [Related]
11. Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.
Petrilli AM; Garcia J; Bott M; Klingeman Plati S; Dinh CT; Bracho OR; Yan D; Zou B; Mittal R; Telischi FF; Liu XZ; Chang LS; Welling DB; Copik AJ; Fernández-Valle C
Oncotarget; 2017 May; 8(19):31666-31681. PubMed ID: 28427224
[TBL] [Abstract][Full Text] [Related]
12. Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity.
Lepont P; Stickney JT; Foster LA; Meng JJ; Hennigan RF; Ip W
Mutat Res; 2008 Jan; 637(1-2):142-51. PubMed ID: 17868749
[TBL] [Abstract][Full Text] [Related]
13. Cellular prion protein (PrP
Provenzano L; Ryan Y; Hilton DA; Lyons-Rimmer J; Dave F; Maze EA; Adams CL; Rigby-Jones R; Ammoun S; Hanemann CO
Oncogene; 2017 Nov; 36(44):6132-6142. PubMed ID: 28692055
[TBL] [Abstract][Full Text] [Related]
14. Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth.
James MF; Lelke JM; Maccollin M; Plotkin SR; Stemmer-Rachamimov AO; Ramesh V; Gusella JF
Neurobiol Dis; 2008 Feb; 29(2):278-92. PubMed ID: 17962031
[TBL] [Abstract][Full Text] [Related]
15. A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.
Beauchamp RL; James MF; DeSouza PA; Wagh V; Zhao WN; Jordan JT; Stemmer-Rachamimov A; Plotkin SR; Gusella JF; Haggarty SJ; Ramesh V
Oncotarget; 2015 Jul; 6(19):16981-97. PubMed ID: 26219339
[TBL] [Abstract][Full Text] [Related]
16. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development.
Fuse MA; Dinh CT; Vitte J; Kirkpatrick J; Mindos T; Plati SK; Young JI; Huang J; Carlstedt A; Franco MC; Brnjos K; Nagamoto J; Petrilli AM; Copik AJ; Soulakova JN; Bracho O; Yan D; Mittal R; Shen R; Telischi FF; Morrison H; Giovannini M; Liu XZ; Chang LS; Fernandez-Valle C
Neuro Oncol; 2019 Mar; 21(4):486-497. PubMed ID: 30615146
[TBL] [Abstract][Full Text] [Related]
17. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.
James MF; Stivison E; Beauchamp R; Han S; Li H; Wallace MR; Gusella JF; Stemmer-Rachamimov AO; Ramesh V
Mol Cancer Res; 2012 May; 10(5):649-59. PubMed ID: 22426462
[TBL] [Abstract][Full Text] [Related]
18. CUDC907, a dual phosphoinositide-3 kinase/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells.
Huegel J; Dinh CT; Martinelli M; Bracho O; Rosario R; Hardin H; Estivill M; Griswold A; Gultekin S; Liu XZ; Fernandez-Valle C
Oncotarget; 2022; 13():890-904. PubMed ID: 35875610
[TBL] [Abstract][Full Text] [Related]
19. Role of Merlin/NF2 inactivation in tumor biology.
Petrilli AM; Fernández-Valle C
Oncogene; 2016 Feb; 35(5):537-48. PubMed ID: 25893302
[TBL] [Abstract][Full Text] [Related]
20. Merlin status regulates p75(NTR) expression and apoptotic signaling in Schwann cells following nerve injury.
Ahmad I; Fernando A; Gurgel R; Jason Clark J; Xu L; Hansen MR
Neurobiol Dis; 2015 Oct; 82():114-122. PubMed ID: 26057084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
